6IBB

Crystal structure of the rat isoform of the succinate receptor SUCNR1 (GPR91) in complex with a nanobody

6IBB の概要

• エントリーDOI: 10.2210/pdb6ibb/pdb
• 分子名称: Succinate receptor 1, Nanobody6, (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate, ... (7 entities in total)
• 機能のキーワード: sucnr1 gpr91 gpcr g-protein coupled receptor nanobody succinate complex, membrane protein
• 由来する生物種: Rattus norvegicus (Norway Rat); 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 116776.95

構造登録者

Haffke, M.,Jaakola, V.-P. (登録日: 2018-11-29, 公開日: 2019-08-14, 最終更新日: 2024-10-23)

主引用文献

Haffke, M.,Fehlmann, D.,Rummel, G.,Boivineau, J.,Duckely, M.,Gommermann, N.,Cotesta, S.,Sirockin, F.,Freuler, F.,Littlewood-Evans, A.,Kaupmann, K.,Jaakola, V.P.
Structural basis of species-selective antagonist binding to the succinate receptor.
Nature, 574:581-585, 2019

PubMed Abstract: The tricarboxylic acid cycle intermediate succinate is involved in metabolic processes and plays a crucial role in the homeostasis of mitochondrial reactive oxygen species. The receptor responsible for succinate signalling, SUCNR1 (also known as GPR91), is a member of the G-protein-coupled-receptor family and links succinate signalling to renin-induced hypertension, retinal angiogenesis and inflammation. Because SUCNR1 senses succinate as an immunological danger signal-which has relevance for diseases including ulcerative colitis, liver fibrosis, diabetes and rheumatoid arthritis-it is of interest as a therapeutic target. Here we report the high-resolution crystal structure of rat SUCNR1 in complex with an intracellular binding nanobody in the inactive conformation. Structure-based mutagenesis and radioligand-binding studies, in conjunction with molecular modelling, identified key residues for species-selective antagonist binding and enabled the determination of the high-resolution crystal structure of a humanized rat SUCNR1 in complex with a high-affinity, human-selective antagonist denoted NF-56-EJ40. We anticipate that these structural insights into the architecture of the succinate receptor and its antagonist selectivity will enable structure-based drug discovery and will further help to elucidate the function of SUCNR1 in vitro and in vivo.

PubMed: 31645725
DOI: 10.1038/s41586-019-1663-8

実験手法

X-RAY DIFFRACTION (2.12 Å)